Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27258849 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1LMNATDP1CYP19A1 | |
| SCHEMBL1446587 | 0.81 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1LMNATDP1CYP19A1 | |
| SCHEMBL8129946 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNATDP1CYP19A1 | |
| SCHEMBL1447446 | 0.81 | EGFR (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL5583829 | 0.80 | LTA4H (0.41) | SMN1; SMN2ALDH1A1LMNAHTTLTA4H | |
| SCHEMBL9922005 | 0.78 | LMNA (0.53) | SMN1; SMN2ALDH1A1LMNATDP1CYP19A1 | |
| SCHEMBL9686796 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNATDP1CYP19A1 | |
| SCHEMBL9686693 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNATDP1CYP19A1 | |
| SCHEMBL9685770 | 0.78 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1LMNATDP1CYP19A1 | |
| SCHEMBL23069171 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNATDP1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| US-7998949-B2 | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-16 | — | — | US | claimed |
| EP-2298305-A1 | 4-(N-Phenylamino)-quinazolines/quinolines as inhibitors of tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | claimed |
| US-20100022505-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | US | claimed |
| EP-1956010-A1 | Bicyclical heterocycles, medicines containing these compounds, their application and method for their production | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-13 | — | — | EP | claimed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-8343982-B2 | Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | disclosed |
| US-7998949-B2 | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2011-03-31 | — | — | US | disclosed |
| EP-2298305-A1 | 4-(N-Phenylamino)-quinazolines/quinolines as inhibitors of tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | disclosed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | disclosed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| EP-1028945-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | Amgen Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024404-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022505-A1 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF | RET, CYP11B2, CHUK | SMN1; SMN2 4691/4885ALDH1A1 1652/4885LMNA 2176/4885 |
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | CYP11B2, CYP11B1, PKD1 | SMN1; SMN2 2512/4885ALDH1A1 683/4885LMNA 869/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | SMN1; SMN2 2655/4885ALDH1A1 731/4885LMNA 783/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | SMN1; SMN2 4567/4885ALDH1A1 1933/4885LMNA 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.